<DOC>
	<DOCNO>NCT03092232</DOCNO>
	<brief_summary>The current study first clinical trial propose PF-06865571 . It design evaluate safety , tolerability , pharmacokinetics ( PK ) follow administration single dose PF-06865571 healthy adult subject .</brief_summary>
	<brief_title>Single Dose Study Assess Safety , Tolerability Pharmacokinetics ( PK ) PF-06865571</brief_title>
	<detailed_description />
	<criteria>Healthy male female nonchildbearing potential ; Age 1855 , inclusive ; Body Mass Index 22.5 35.4 kg/m2 , inclusive ; Body weight &gt; 50 kg ; Not prescription nonprescription drug within 7 day 5 halflives prior first dose . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergises , exclude untreated , asymptomatic , seasonal allergy time dose ) Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug test . History regular alcohol consumption exceed 7 drinks/week female subject 14 drinks/week male subject ( 1 drink = 5 ounce [ 150 mL ] wine 12 ounce [ 360 mL ] beer 1.5 ounce [ 45 mL ] hard liquor ) within 6 month screen . Treatment investigational drug within 30 day ( determined local requirement ) 5 half life precede first dose investigational product ( whichever longer ) . Fertile male subject unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product . Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 60 day prior dose . History sensitivity heparin heparin induce thrombocytopenia . History human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ; positive testing HIV , hepatitis B surface antigen ( HepBsAg ) , hepatitis B core antibody ( HepBcAb ) , hepatitis C antibody ( HCVAb ) . Fertile male subject unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product . Subjects ANY follow abnormality clinical laboratory test screen , assess study specific laboratory confirm single repeat test , deem necessary : ( 1 ) Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) level , total bilirubin &gt; upper limit normal ( ULN ) ; ( 2 ) For optional Cohort 3 , AST ALT great equal 1.5 × ULN , provide data Cohorts 1 2 support limit ; ( 3 ) • Subjects history Gilbert 's syndrome may direct bilirubin measure would eligible study provide direct bilirubin level less equal ULN plus ALT AST less equal ULN plus alkaline phosphatase , hemoglobin , reticulocyte count less equal ULN . Unwilling unable comply criterion Lifestyle Requirements section protocol . Subjects investigator site staff member directly involved conduct study family member , site staff member otherwise supervised investigator , subject Pfizer employee , include family member , directly involve conduct study . Other acute chronic medical psychiatric condition include recent ( within past year ) active suicidal ideation behavior laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>